Published in Medical Letter on the CDC and FDA, July 15th, 2001
Produced by Immunetics, Inc. of Cambridge, Massachusetts, the new assay recently won approval from the U.S. Food and Drug Administration (FDA) for use as a diagnostic test for Lyme disease.
It is the first diagnostic tool to use a synthetic product called C6, a hybrid chemical marker based on components derived from the surface of Borrelia burgdorferi, the tick-borne bacterium that causes Lyme disease. The C6 test is sensitive only to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA